The early history of neuropsychology developed around the study of brain-behavior relationships as influenced by structural lesions. By contrast, neuropsychologists have only more recently started to appreciate the impact of psychopharmacology on cognitive functioning, and most of this attention has been given to illicit drugs. While commonly used, medications with potential cognitive effects have received relatively little attention both in research and in clinical practice (Hartman, 1995) .
The early history of neuropsychology developed around the study of brain-behavior relationships as influenced by structural lesions. By contrast, neuropsychologists have only more recently started to appreciate the impact of psychopharmacology on cognitive functioning, and most of this attention has been given to illicit drugs. While commonly used, medications with potential cognitive effects have received relatively little attention both in research and in clinical practice (Hartman, 1995) .
A large minority of the population uses psychotropic medications and other compounds that influence neuropsychological functioning. One estimate of antidepressant use is 1.6% used, including many that occur in patients presenting for neuropsychological evaluation. These include the use of the MAO inhibitor, selegiline, for Parkinson's disease (Heinonen & Rinne, 1989) , TCAs for chronic pain (Adams & Victor, 1989) and for agitation following TBI (Jackson & Mysiw, 1989) , selective serotonergic reuptake inhibitors (SSRIs) and clomipramine for obsessive-compulsive disorder (Lydiard, 1994) , and various other antidepressants for attention deficit disorder (Gualtieri & Evans, 1988) . For a listing of antidepressant medication and their brand names see Table 1 .
Research showing roughly equivalent efficacy of most of the commonly used antidepressants (Gelenberg & Schoonover, 1991) has led to prescription practices frequently guided by side-effect profiles. Much of the challenge in effective antidepressant pharmacotherapy is based on careful attention to these side effects (McElroy, Keck, & Friedman, 1995) . While reviews of early research yielded rather inconsistent neuropsychological results (Deptula & Pomara, 1990; Hartman, 1988; Sakulsripong, Curran, & Lader, 1991) , most recent studies using double-blind, placebo-controlled designs point to more consistent and distinct cognitive patterns associated with the major classes of antidepressants (i.e. heterocyclics, SSRIs, and MAO inhibitors). Of particular concern are the anticholinergic effects, due to the recognized importance of the cholinergic system in memory functions. Awareness of these patterns are useful to the neuropsychologist not only in interpreting cognitive dysfunction, but also in terms of contributing to a collaborative effort with the prescribing physician in maximizing the cost-benefit ratio of pharmacotherapy and quality of life.
Tricyclics and Heterocyclics
The TCAs and heterocyclics are important to cognitive functioning as a result of their varying sedative and anticholinergic effects. Both studies of nondepressed and depressed individuals indicate selective cognitive impairment in selected domains.
Studies of individuals without reported disability.
Among healthy, nondepressed subjects single doses of amitriptyline (50 mg) produced maximal sedation, impaired coordination, and decreased digit-symbol substitution at 3 to 4.5 hours after ingestion (Mattila, Mantilla, Vrijmoed-de Vries, & Kuitunen, 1989) . A similar study protocol yielded decreased finger tapping rate and digit-symbol substitution (Lader, Melhuish, Frcka, Fredricson Overo, & Christensen, 1986) . Single doses of amitriptyline (50 mg) administered to healthy elderly produced comparable results with psychomotor and sedative measures correlating with plasma amitriptyline levels (Ghose & Sedman, 1987) . In administering a wider range of neuropsychological tests (i.e., CFF, choice RT, ''manual dexterity,'' and digit span), Warrington et al. (1986) found single doses of both trazodone (100 mg) and amitriptyline (50 mg) to show a substantial depressant effect on all measures except digit span.
Single doses of imipramine ranging from 25 mg to 50 mg in healthy, nonelderly adults produced no notable impairment, but decrements in psychomotor and memory performance more consistently appear at 75 mg (Holmberg, 1981; Jones, Allen, Griffiths, Marshall, & Richens, 1986; Landauer & Milner, 1971; Saletu, Grunberger, Rajna, & Karobath, 1980) . Relative to driving behavior, a recent, a well-designed study of healthy adults and elderly administered 75 mg imipramine resulted in substantial impairment relative to placebo on a standardized, in-traffic driving test for younger adults but, curiously, not for elderly subjects (van Laar, van Willigenburg, & Volkerts, 1995) .
Another double-blind, crossover study of healthy adults compared progressive dosing over 14 days of amitriptyline (37.5-75 mg), trazodone (100-200 mg), and placebo (Sakulsripong, Curran, & Lader, 1991) to determine the presence of tolerance to sedative and amnestic effects of these drugs. Tolerance on psychomotor measures was not found. The time since last dose was a substantial determinant in both sedation and psychomotor effects. Furthermore, when subjective measures of sedation were covaried on psychomotor performance, there were no impairments indicating that psychomotor decrements were primarily a function of arousal. This replicates their earlier finding comparing four antidepressants with varying sedative and anticholinergic qualities (Curran, Sakulsripong, & Lader, 1988) . Even after covarying for sedation, amitriptyline produced a greater impairing effect on memory than trazodone. Also impaired were digit symbol, digit span, CRT, and finger tapping rates, while category fluency was not affected by either drug. Trazodone has a low anticholinergic effect. This combined with its weaker memory impact is consistent with research on the role of the cholinergic system in memory (Lezak, 1995) .
In another study with the same design comparing clomipramine, alprazolam and placebo, clomipramine produced roughly the same effects as amitriptyline in the Sakulsripong et al. (1991) study, with the exception that clomipramine accumulated effects until day 5 with only some recovery by day 10. The results suggested that tolerance develops slowly over a 3-week period with clomipramine. This may be a function of the longer half-life of clomipramine (24 hours) compared to amitriptyline (16 hours; Gelenberg & Schoonover, 1991) . This suggests the importance of absorption and elimination in determining the potential for acute, subacute and chronic effects of TCAs on neuropsychological functioning.
In a comparison of single doses of 50 mg amitriptyline to 100 mg desipramine, a low anti-cholinergic TCA, and 200 mg zimelidine (no longer available in the U.S. market) administered to healthy male adults, amitriptyline adversely affected tracking and information processing while desipramine produced milder (Linnoila et al., 1983) or no adverse effects along with zimelidine (Linnoila et al., 1984) .
While the neuropsychologist is unlikely to conduct a comprehensive exam with a patient who is delirious, consultations are frequently requested for acute mental status changes that are sometimes related to TCA or other psychotropic toxicity. Such toxicity occurs in approximately 6% of patients (Preskorn & Jerkovich, 1990) . Based on their study of a series of patients with high TCA plasma levels, Meador-Woodruff and colleagues (1988) recommend not only careful clinical monitoring but also liberal use of plasma TCA levels. The neuropsychologist should be familiar with target TCA levels and be cognizant of the time since the last dose of medication. This may be especially important for those with compromised liver function, patients on polypharmacy, and others for whom drug absorption and metabolism may be variable.
Studies in clinical populations.
Numerous studies have assessed the neuropsychological impact of TCAs in populations of specific interest to the neuropsychologist. The clinical literature is characterized by a wide variety of tests. For example, one review of the cognitive effects of TCAs and other anti-depressants among depressed elderly found 70 distinct tests among 18 studies (Knegtering, Eijck, & Huijsman, 1994) . In general, the same highly sedating and anticholinergic TCAs that produce adverse attention and memory effects in healthy adults, show the same pattern of short-term adverse effects in clinical populations. Under chronic administration, clinical populations may take longer to show normalization of cognitive tests (Amado-Boccara et al., 1994) , but these adverse effects may be partially offset by the potential benefits of successfully treating the depression or other clinical conditions. Poststroke depression is a common occurrence and may last well into the recovery period. While a review of TCA use in post-stroke depression (Fedoroff & Robinson, 1989) , concluded that TCA treatment may lead to improved activities of daily living (ADLs) and cognitive functioning, the less sophisticated designs make inferences questionable. In another potential indication for TCAs, the use of imipramine with attention deficit-hyperactivity disorder under double-blind, placebo-controlled, cross-over conditions, resulted in adverse dose-response effects on motor speed and motor pursuit while improving attention and hyperactive behavior (Gualtieri & Evans, 1988) . The use of desipramine for attention deficit disorder has not shown a consistent benefit (e.g., Gualitieri, Keenan, & Chandler, 1991; Rapport, Carlson, Kelly, & Pataki, 1993) .
In summary, TCAs have their greatest effects on psychomotor and memory functioning. The sedative qualities of the TCA are most important in psychomotor measurement, while both sedative and anticholinergic aspects appear responsible for adverse memory effects. The generalizability of formal testing to daily functioning has been linked in several studies. Partial tolerance typically develops, but the time course may be dependent on plasma levels, which have been shown to be significantly correlated acutely with relevant neuropsychological measures. Clinical samples administered TCAs show distinctive patterns of cognitive effects that likely interact with the neuropsychological consequences of the clinical disorders and their amelioration.
MAO Inhibitors
Use of monoamine oxidase inhibitors (MAOIs) started in the 1950s as the earliest effective pharmacotherapeutic agents for depression (Gelenberg & Schoonover, 1991) . While more infrequently used today, isocarboxazid, phenelzine, and tranylcypromine are utilized selectively for depression. Other MAOIs are in use, such as low dose selegiline for Parkinson's disease (Heinonen & Rinne, 1989 ) and a newer class of reversible MAOIs, most notably moclobemide, that show promise in treatment of depression and panic disorder (Priest, Gimbrett, Roberts, & Steinert, 1995) . As is common among antidepressants, efficacy of the drugs currently in use are roughly equal in efficacy to other antidepressants, resulting in application based on side-effect profiles and individual tolerance. The most serious side effect of the irreversible MAOIs is hypertensive crisis induced by tyramine accumulation, which does not appear with reversible MAOIs (Priest et al., 1995) .
Despite a favorable cholinergic profile relative to TCAs that would suggest less adverse effects on memory, little research on the irreversible MAOIs can be found that addresses the issue. Studies of individuals without psychiatric disturbance administered these drugs are essentially absent in the literature. The research on clinical populations has focused on the elderly depressed typically in clinical trials comparing MAOIs to TCAs based on the greater potential for adverse cognitive effects in this population. Typically, these studies have shown no cognitive effects, but this was also true of alternative treatments and placebos (e.g., Georgotas et al., 1989; Georgotas, Reisberg, & Ferris, 1983) prompting methodological concerns. A concern with patients on MAOIs is the risk of impaired cognition during medication withdrawal (Halle & Dilsaver, 1993) . Moclobemine, a novel reversible MAOI largely devoid of anticholinergic effects, shows no significant adverse cognitive effects and may even prove superior to placebo in its cognitive profile for depressed individuals (Allain et al., 1992; Fitton, Faulds & Goa, 1992) . Selegiline (L-deprenyl) was the focus of a large multicenter trial in the treatment of early, untreated Parkinson's disease (Kieburtz et al., 1994) . While motor symptoms of the disease fared better than placebo, no effect on cognitive performance was found. Use of selegiline for Alzheimer's disease has shown inconsistent results.
In summary, there is a strong theoretical basis for the cognitive superiority of MAOIs over TCAs, yet little research has addressed this, aside from the promising reversible MAOIs that may come into clinical use soon in the United States. No comparison in cognitive effects can be made to SSRIs for lack of published research. However, based on side-effect profiles and their relatively mild effects on cognition, the MAOIs and SSRIs would be expected to be comparable in degree of cognitive effect though distinct in their patterns.
SSRIs
Most serotonergic reuptake inhibitor (fluoxetine, paroxetine, sertraline, fluvoxamine, clovoxamine, and nefazodone) research with human subjects has been published in the past 10 years. It has been only since 1990 that published research has addressed the potential cognitive effects of these drugs. Of this research, much of it is conducted within the context of clinical drug trials comparing them to placebo, standard TCA therapy, and other SSRIs. Commonly, only one or two neuropsychological measures are administered, typically assessing psychomotor speed or verbal memory, in these mostly industry-sponsored studies. The dramatic rise in the popularity of SSRIs in recent years strongly suggests that further research in this area is necessary.
Fluoxetine quickly became a major competitor to the TCAs, for its comparable efficacy with a more acceptable side-effect profile. The only study of the cognitive effects of fluoxetine in nondepressed adults was of a group of smokers administered either a large dose (60 mg/ day) or placebo for 1 week (Stein, Jarvik, & Gorelick, 1993) . Rey Auditory Verbal Learning Test performance was lower in the fluoxetine group on Trial 1 (SD ϭ 0.74), but was compensated for with greater learning on Trials 2 through 5. This was interpreted as either memory impairment or a difficulty in shifting set. However, it should be noted that few patients are placed on such a high dose of fluoxetine, especially without titration.
Among reports of cognitive effects of fluoxetine specifically for depressed individuals, there is a curious dichotomy. There are numerous case reports indicating a temporal association of memory or other cognitive impairment with fluoxetine (Bangs, Petti, & Janus, 1994; Bradley & Kulik, 1993; Friedman, 1994; Geldmacher, Waldman, Doty, & Heilman, 1994; Mirow, 1991) . By contrast, double-blind trials commonly report an advantage of fluoxetine over one of the TCAs (e.g., Keegan et al., 1991; Richardson et al., 1994) . Despite these attempts at assessing the cognitive effect of fluoxetine in depressed individuals, no study has integrated well-validated neuropsychological measures with adequate sample size and commonly used dosages. Furthermore, there appears to be no published report on fluoxetine using a placebo control in a clinical sample. It remains unresolved whether fluoxetine produces any adverse neuropsychological effects relative to placebo or nonpharmacological treatment.
Sertraline's effects on cognitive functioning in depressed individuals has not been addressed in the published literature. Studies on nonpatients have been small (n Ͻ 12), which makes finding clinically significant effects difficult. A small study of healthy women showed no effect on choice reaction time (CRT; Hindmarch & Bhatti, 1988) . Two other studies using elderly subjects showed no differences between sertraline (100 mg) with placebo on digit span, word list learning, and digit symbol substitution while single dose amitriptyline (Mattila, Saarialho-Kere, & Mattila, 1988) and sustained administration (9 days) of mianserin (Baksi, Hindmarch, & Shillingford, 1988 ) produced significant impairment.
Paroxetine has been the subject of least two studies with nondepressed individuals and two studies with depressed individuals. Both studies, with small samples of nondepressed young adults (Hindmarch, 1992) or elderly adults (Kerr, Fairweather, Mahedran, & Hindmarch, 1992) , used a 14-day administration, placebo-controlled, cross-over design with CRT, a Sternberg task, a Stroop task with nonverbal responses, and a visual tracking task. No clinically meaningful differences from placebo were found on cognitive measures. In a large, 6-week clinical trial of paroxetine and fluoxetine but no placebo, Mini-Mental Status Exam performance was significantly higher for the paroxetine group at week 3 but not at week 6 (Geretsegger, Bohmer, & Ludwig, 1994) . This study and one with a cursory description by Hindmarch (1992) do not resolve the issue of clinically significant effects of paroxetine on cognitive functioning; nor do the small studies to date in individuals without mood disturbance provide any substantive direction.
Recently approved nefazodone (100 mg and 200 mg twice daily) has been studied in a single study of healthy adults and elderly comparing its effects with imipramine (50 mg twice daily) and placebo acutely and with subchronic dosing (van Laar et al., 1995) . After a single dose, a standardized on-road driving test showed no change to mild improvement in driving compared to placebo, which was superior to imipramine. However, after 7 weeks nefazodone produced slight impairment in driving, in addition to dose-related impairment of memory and other cognitive measures, which were correlated with plasma concentrations.
In summary, the SSRI research presents an incomplete picture of their cognitive effects. While they clearly produce smaller decrements in performance than the TCAs, there is no substantial evidence regarding SSRI effects compared to placebo in clinical populations. Studies of healthy subjects lend little guidance in what effects may be present in clinical populations. It is instructive that, in the one study reporting correlation of plasma levels and cognitive performance, an adverse effect on performance was found.
ANXIOLYTICS
Anxiolytics are commonly used by patients presenting for neuropsychological assessment. Their use for anxiety disorders, sleep disturbance, agitation, irritability, seizures, and alcohol withdrawal may all result as a function of pathological processes that are directly responsible for referral to neuropsychological services. Patients may also receive these medications for premorbid disorders or as inappropriate primary treatment for a poorly diagnosed, cognitively-impairing condition, such as can be found when mood and anxiety symptoms are prominent features of an undiagnosed dementia. For a listing of anxiolytic medications cited, see Table 2 .
Benzodiazepines
Until the late 1950s when the first benzodiazepine, chlordiazepoxide, became available, barbiturates and meprobamate were the primary medications for treatment of anxiety. These were welcomed alternatives to medications that produced substantial sedation, central nervous system (CNS) depression, cognitive interference and safety concerns (Bernstein, 1988; Schnabel, 1987) . In time, the benzodiazepines gained their own reputation for abuse potential and adverse effects on attention, psychomotor functioning, and memory. Yet, the benzodiazepines are the most widely prescribed drugs of any type (Rosenbaum & Gelenberg, 1991) , and as recently as 1987, 11% of American adults had used an anxiolytic (Dubovsky, 1990; Sussman & Chou, 1988) . Early clinical reports suggested that benzodiazepines could adversely affect memory (e.g., Greenblatt & Shader, 1974) . This was confirmed by later controlled trials, in which it became clear that such effects could be demonstrated in all benzodiazepines, varying according to route of administration, dose and specific pharmacokinetics (Roth, Roehrs, Wittig, & Zorick, 1984) . Due to the substantial variability in dosages used, tests administered and time of administration, it is a cumbersome task to ascertain the effects of each benzodiazepine and make comparisons among them in a reasonably concise manner. Therefore, the benzodiazepines will be reviewed with attention to the types of impairment commonly found and to the broad factors that appear to substantially influence cognitive functioning (i.e., half-life, dose, concurrent alcohol, or psychotropic medication use, affinity for benzodiazepine receptor site binding, route of administration, time since last dose, length of use/tolerance, age of user, and effects on clinical populations).
The primary receptor directly stimulated by benzodiazepines is the gamma-amino butyric acid (GABA) receptor or the benzodiazepine-GABA receptor complex. In a review of the GABA antagonists, such as flumazenil, Barbee (1993) concluded that such drugs block the amnestic effects of benzodiazepines. The GABA action may simply be an intermediate step in the production of amnestic effects as it appears to have anticholinergic effects in the basal forebrain (Julien, 1995) . This anticholinergic response would be consistent with that of the memory-impairing TCAs. A series of studies tracking both sedation and memory following short-term and long-term use led Barbee (1993) and others (Hommer, 1991; Julien, 1995) to conclude that, while the two effects are related, they represent distinct phenomena. The long-term studies converge on the conclusion that tolerance to sedative effects is routine, but amnestic effects tend to persist. Thus, it is not prudent to make substantial inferences regarding benzodiazepine-induced memory decline from the observed degree of sedation unless administration is acute. Furthermore, tolerance to sedative effects during chronic benzodiazepine use may lead to increases in the amount or frequency of dosing which, in turn, further exacerbates the amnestic effects. By contrast, psychomotor impairment and slowed motor speed is well-correlated with sedation for both the acute and chronic conditions. Speed of performance appears to be the most consistently affected within the benzodiazepine-sleep deprivation literature (Johnson & Chernik, 1982) .
Guidelines for the Neuropsychological Assessment of Patients Using Benzodiazepines
In general, the benzodiazepines with the longest mean half lives, such as chlordiazepoxide (10 hours), diazepam (24 hours), and flurazepam (80 hours), commonly yield the very persistent active metabolite nordiazepam (60 hours); by contrast short acting agents, such as alprazolam (12 hours), oxazepam (8 hours), and triazolam (2.5 hours) do not have active metabolites (Julien, 1995) . This factor is vital to the neuropsychologist's assessment of the potential impact of these medications on the clinical evaluation. For patients on chronic doses, there are at least three important guidelines. First, with recent onset of benzodiazepine use, steady state concentrations occur after about four half-lives (Rosenbaum & Gelenberg, 1991) . This can be a period as long as several weeks for a healthy, young adult using a long-acting benzodiazepine and on no other medications. Second, recently discontinued use is also important to assess, because drug elimination takes approximately six half-lives (Holford & Benet, 1995) . Third, the nature of drug tapering is important, especially for the short-acting benzodiazepines that produce a more precipitous drop in blood levels. Thus, the neuropsychologist should be aware of all benzodiazepine use in the past month, with special attention to use in the previous week.
The issue of age is relevant for several reasons. When considering reasons for benzodiazepines administration, one should be mindful that the elderly are more likely to exhibit impaired memory with anxiety and depression (Deptula, Singh, & Pomara, 1993; Mejo, 1992) . Being already predisposed to such memory decline, they note more negative side effects in general when on benzodiazepines (Wysowski & Barash, 1991) . On the other hand, embarrassment may accompany the experience of memory decline (Barbee & McLaulin, 1990) , which may present to the neuropsychologist as a patient unwilling to acknowledge difficulties (and appearing to have poor insight) that significant others readily report. This may be further aggravated by the sometimes gradual and delayed onset of amnestic properties that makes linking it to medication difficult. In terms of pharmacokinetics, half-life increases with age. This is largely not a function of metabolic processes, but rather changes in the volume of distribution (Klotz, Avant, Hoyumpa, Schenker, & Wilkinson, 1975) . Therefore, intact liver function testing in elderly patients may accompany age-related sensitivity to benzodiazepines. Nevertheless, those with liver disease can exhibit a two-fold prolongation in the half-life of diazepam compared to age-matched elderly controls (Klotz et al., 1975) .
Memory is not uniformly affected by benzodiazepines. Short-term storage capacity, such as that required for digit recall, appears unaffected (Brown, Lewis, Brown, Horn, & Bowes, 1982; Curran, Schiwy, & Lader, 1987; Mac, Kumar & Goodwin, 1985) as is the case for procedural memory (Lister & File, 1984) . While benzodiazepines do not affect retrieval of information learned prior to administration, they do impair acquisition of new information during drug exposure (Brown et al., 1982; Lister & File, 1984; Preston, 1988) and result in faster rates of forgetting under such circumstances (Barbee, Black, & Todorov, 1992) . Thus, impaired memory consolidation (anterograde amnesia) appears to be the crucial factor.
Generalization of laboratory findings to daily life is always a concern in neuropsychological assessment. In an extensive review of the amnestic effects of benzodiazepines, Barbee (1993) warns that the memory tasks used in the laboratory may have unacceptably low relevance to everyday functioning. Roth and colleagues (1990) also question external validity of these cognitive studies. This may contribute, in part, to the week correlation between objective findings and subjective reports of memory functioning. In the literature, subjective reports are inconsistently reported concurrently with objective measures. Patients commonly underestimate the adverse effects of benzodiazepines on their memory functioning (Roache & Griffiths, 1985; Hinrichs, Mewaldt, Ghoneim, & Berie, 1982) .
Consideration of clinical studies requires attention to specific disorders that are being treated. Those with anxiety frequently note forgetfulness and poor concentration. It cannot be assumed that benzodiazepines exacerbate these symptoms, as the importance of the arousalperformance Yerkes-Dodson (inverted U) curve must be considered. Some studies of benzodiazepines administered acutely to highly anxious patients have yielded improved memory performance (Desai, Taylor-Davies, & Barnett, 1983; Koeppen, Netter, & Fischer, 1985; Kohner & Lienert, 1980) . By contrast, there do not appear to be any studies of long-term use suggesting improvement. As for patients suffering from insomnia, memory and other performance effects have been smaller than that for nonpatients in the published literature. Roth et al. (1990) suggest that this is a function of a more heterogeneous population among insomniacs, rather than the more tempting explanation that those suffering from insomnia balance the traditional adverse effects with the benefits of improved sleep. Overall, from a purely neuropsychological standpoint, successful treatment of a clinical condition may be of some cognitive benefit, but the costs of benzodiazepine use, especially on a long-term basis, likely eliminates any such benefit. Potential relief of the clinical condition may be more important to the patient than these cognitive effects, but the neuropsychologist can assist the patient and prescribing physician in illuminating the often unrecognized negative cognitive effects of benzodiazepines. Behavioral treatments should be presented as one alternative to cognitively-impairing pharmacological treatments.
In summary, all benzodiazepines exhibit some psychomotor and memory impairment. While psychomotor effects tend to resolve with tolerance to sedation, amnestic effects mostly persist. Impaired vigilance does not appear to be explained simply by sedation, and repeated dosing commonly does not substantially diminish this effect (Koelega, 1989) . The temporal patterns of use and discontinuation are vital to understanding potential adverse effects. Some groups, such as the elderly, are at heightened risk not only for benzodiazepine-induced cognitive impairment, but may suffer disproportionately in terms of additive effects with neurodegenerative processes, the synergistic effects with medications or alcohol, and physical risk (e.g., falls). Assessment of these effects is crucial due to poor subjective awareness and the difficulty in the temporal linkage of cognitive deficits, especially with the longer acting benzodiazepines.
Atypical Anxiolytics
Buspirone is an antianxiety agent that, unlike benzodiazepines, does not have hypnotic, anticonvulsant or muscle relaxant properties. Chemically, it also differs in not directly affecting the GABA receptor (Barrett, Witkin, Mansback, Skolnick, & Weissman, 1986) , but appears to produce its effects as a partial 5-HT 1A agonist (Taylor, 1988) . Anti-anxiety action commonly takes up to a week in contrast to the fast onset observed with benzodiazepines. Buspirone has the benefit of being devoid of significant withdrawal symptoms (Murphy, Owen, & Tyrer, 1989; Rickels, Schweizer, Csanalosi, Case, & Ghung, 1988) .
In a single-dose study of individuals without psychological disability administered low to moderate doses of buspirone (5 and 10 mg) indicates an advantage on a modified version of the Randt Memory Test including the 15-Item Word List (learning and immediate and 24 hours recall), Paired Words and Picture Recognition over comparable doses of alprazolam (0.5 and 1 mg) and no difference from placebo (Barbee, Black, Kehoe, & Todorov, 1991; Barbee, Black, & Todorov, 1992) . For all measures, except for Paired Words immediate recall, 5 mg buspirone showed an advantage over 1 mg alprazolam. A similar study using moderately-high dose diazepam (15 mg) and buspirone (15 mg), but with a broader range of tests showed the expected prominent adverse effects of diazepam but not of buspirone (Unrug-Neervoort, van Luijtelaar, & Coenen, 1992) . While there were no differences for any drug based on word fluency, digit span forward, dominant finger tapping, buspirone showed a specific advantage (and no difference from placebo) on digit span backward, Taylor complex figure delayed recall, 15-word Trial 5 recall and delayed recall, and pegboard.
A clinical study of single-blind buspirone and diazepam using patients with generalized anxiety disorder treated for 4 weeks showed diazepam, but not buspirone, to have significant impairment on a 100-kilometer on-road driving test during the first 3 weeks of treatment (van Laar et al., 1992) . Speed control was specifically impaired by diazepam during the first week. Studies of the use of buspirone for the elderly or for other diagnoses are sparse and do not yield any clear conclusions at this point.
Conclusions
In summary, all benzodiazepines exhibit dose-dependent persisting memory impairment and predominantly sedation-dependent psychomotor effects, which diminished with tolerance to the sedative effect. Impaired vigilance does not appear to be explained simply by sedation, and tolerance is commonly not substantial. A detailed recent drug use history is essential to fully appreciate the potential acute, chronic and withdrawal effects on formal assessment and daily functioning. By contrast buspirone appears to be largely devoid of adverse neuropsychological impairment as determined by both a broad range of standardized cognitive tests and by assessment of adaptive functioning (i.e., driving). However, it suffers from a longer onset in therapeutic action of up to 1 week, unlike the acute onset of the benzodiazepines' antianxiety effect.
STIMULANTS
The sympathetic nervous system is critical in the regulation of those organs necessary to manage the ''fight-or-flight'' response and more general responses to stress. Chemically, this modulation is primarily a function of norepinephrine and epinephrine activity. Substances that mimic these functions are known as sympathomimetics. Such sympathomimetics are found both among prescribed and illicit drugs. The primary clinical uses of sustained oral sympathomimetic medications are to treat narcolepsy (dextroamphetamine, methylphenidate), attention deficit hyperactivity disorder (ADHD; dextroamphetamine, methamphetamine, methylphenidate, pemoline), obesity (amphetamine/dextroamphetamine, fenfluramine, methamphetamine, phentermine), and nasal congestion (phenylpropanolamine, pseudoephedrine). ADHD may by itself adversely effect neuropsychological functioning. While out of favor for decades, stimulants may be of some benefit for certain depressed populations, such as people with AIDS (Massand & Tesar, 1996) . For a listing of cited stimulant medications, see Table 3 .
While the focus of this article is on prescription medications, the neuropsychologist should be aware of sympathomimetics in nonprescription medications and herbal preparations. Among the most obvious compounds is caffeine, found not only in coffee, tea, iced tea and cola, but also in analgesics (e.g., Anacin, Excedrin) and anti-drowsiness medicines (e.g., NoDoz). Nicotine, a cholinergic agonist, is another stimulant in widespread use which, when taken in via tobacco, may exert positive but very short-lived effects on attention due to only a brief (e.g., 10-15 minutes) surge in blood levels (Grassi et al., 1994) . Pseudoephedrine is primary among nonprescription oral decongestants, popular among those individuals self- revealed no studies on the cognitive effects of pseudoephedrine. Queries should also be made regarding herbal preparations, especially those for which the patient takes to increase ''energy.'' Many patients mistakenly assume these substances are safe and without side effects and may take high doses of herbs, such as ephedra, from which ephedrine and other stimulants are derived. Unfortunately, the literature is devoid of controlled studies of these substances. Among healthy individuals, acute moderate dose administration of stimulants have shown mild improvements of some cognitive measures under certain conditions. In studies where a range of cognitive measures were administered, tests of vigilance were most sensitive to the effects of stimulants (Koelega, 1993) . It is unclear how much of the positive cognitive effects of stimulants are a function of reducing fatigue (Rapoport et al., 1980; Weiss & Laties, 1962) . Responses to stimulant medication lead to performance roughly reflective of the Yerkes-Dodson curve, wherein moderate doses appear to lead to moderate arousal and maximal performance. Normal adults administered such a moderate single dose (0.25 mg/kg dextroamphetamine) submitting to serial testing produced the fewest learning errors, as plasma concentration peaked 2 to 3 hours after taking the medication (Kupietz et al., 1985) . Performance improvements on the Bushcke Selective Reminding Test and in reaction time have been found with a single 20 mg dose of methylphenidate administered to 48 healthy young adults (Camp-Bruno & Herting, 1994) .
Among those with clinical conditions being treated by stimulants, individuals with ADHD have, by far, been the best researched for their neuropsychological responses. Over 100 studies have been published on the effects of CNS stimulants for ADHD, primarily with schoolage children. It is generally reported that upwards of 70% of children with ADHD will exhibit a positive behavioral response to one of these stimulants (Cantwell, 1996) . Targeted neuropsychological measures, such as those emphasizing vigilance and verbal memory, frequently show distinct improvement for this population. Generally, as a group, the performance levels during medicated periods improve and approach that for non-ADHD children. Continuous performance tasks (CPT) commonly show decreases in errors of commission and omission among groups of children with ADHD in response to stimulants (e.g., Barkley, DuPaul, & McMurray, 1991; Barrickman et al., 1995) . Commission and omission errors may be more common among those unmedicated attention deficit children with hyperactivity while deficits in retrieval may be more commonly seen in children with attention deficit without hyperactivity; methylphenidate at 5 to 15 mg improves performance in these areas, but individual improvements were loosely associated with dose (Barkley et al., 1991) .
There have been recent attempts to improve attention deficits in acutely brain-injured individuals. A recent review by Kraus (1995) of 11 head injury and stroke studies found mostly uncontrolled case studies. Among the controlled studies available, methylphenidate (15 mg twice daily) administered to 11 acutely brain-injured adults in an A-A-B-A design resulted in improved performance on Digit Span, Mental Control, and Symbol Search among nine attention measures (Kaelin, Cifu, & Matthies, 1996) . By contrast, 12 chronic closed head injury (CHI) patients administered a larger dose of methylphenidate (0.3 mg/kg twice daily) during a double-blind, placebo-controlled, cross-over study showed no significant differences on measures of attention, learning, and cognitive speed (Speech, Rao, Osmon, & Sperry, 1993) . While replication is needed, there may be a positive effect of methylphenidate on attention in acute brain-injury, but no effect among chronic CHI.
In conclusion, stimulants such as methylphenidate, pemoline, and dextroamphetamine can have positive effects on vigilance and memory. The highest rate of responders is in the ADHD population, though significant benefits have been found for acute brain injury. Under ideal conditions, each patient would be administered at least two doses of medication and placebo under blinded and controlled conditions due to the individual variability in responses and nonlinear dose-response curves. There is insufficient evidence on most other stimulant medications. Yet the neuropsychologist should be aware that they may have significant impacts, both positive and negative. Finally, abusive and chronic high-dose stimulant intake may lead to impaired cerebrovascular functioning, such that attention, memory, and processing speed may actually be impaired (Strickland & Stein, 1995) .
ANTIHYPERTENSIVES
Hypertension is a common presentation among patients receiving neuropsychological services, both as comorbid disease and as a direct cause of conditions such as vascular dementia, which are a typical focus of referrals. Prevalence is higher for the elderly and in some ethnic groups, such as African Americans (Syme et al., 1974; Thompson, 1980) . Risk for brain, heart, and kidney damage is directly related to the extent of blood pressure elevation, including mild hypertension (Ն140/90 mm Hg), and control of hypertension has been shown to reduce this risk (Helgeland, 1980) . Unfortunately, many antihypertensives have moderate to high rates of adverse side effects, which patients may find so undesirable as to discontinue their use. Any analysis of a patient's antihypertensive use of antihypertensives relative to cognitive functioning must consider the possibility of the potentially serious side effect of hypotension.
Several classes of antihypertensives affecting unique aspects of blood pressure regulation are available including diuretics (e.g., hydrochlorothiazide, furosemide, triamterene), angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril, enalapril, captopril), calcium channel blockers (e.g., verapamil, diltiazem, nifedipine), and alpha-(e.g., clonidine) and betaadrenergic blockers (e.g., propanalol, atenolol, metoprolol). For a listing of cited antihypertensive medications, see Table 4 . In moderate to severe hypertension, polypharmacy is common (Benowitz, 1995) . How these medications affect neuropsychological functioning is, in part, a function of their peripheral versus central nervous system action. While CNS action has an obvious potential for impacting neuropsychological functioning, peripheral action may influence functioning through general physiological arousal and other autonomic activity (Noyes, 1982; Paykel, Fleminger, & Watson, 1982) . Furthermore, specific changes in blood pressure can be influential. An intriguing finding is that biofeedback management of blood pressure has been shown to improve cognitive functioning both in laboratory testing (Goldman, Kleinman, Snow, Bidus, & Korol, 1975) and in daily functioning (Kleinman, Goldman, Snow, & Korol, 1977) . 
Diuretics
Diuretics, based on their side-effect profile and price, are popular among the antihypertensives. Their apparent lack of direct action within the CNS suggests their safety from a neuropsychological perspective. While one study showed lowered subjective reports of work performance (Williams, Croog, Levine, Testa, & Sudilovsky, 1987) and small but significant adverse effects on psychomotor performance (Currie, Lewis, McDevitt, Nicholson, & Wright, 1988) , overall, no consistent neuropsychological changes have been observed with chronic diuretic treatment of hypertensive patients.
ACE Inhibitors
ACE inhibitors, popular for their reported favorable side effect profile (Edwards, Coulter, Beasley, & MacIntosh, 1987) , have received relatively less attention as a newer class of antihypertensives. Studies are restricted to memory, attention, and psychomotor assessment. Psychomotor speed actually improved in all three studies in which it was addressed (Frcka & Lader, 1988; Herrick et al., 1989; Olajide & Lader, 1985) . Subjective ratings of alertness are often higher when compared to other antihypertensives, but this has not translated into findings of greater performance on measures of attention (Bulpitt & Fletcher, 1992) . Memory was impaired in only one (Frcka & Lader, 1988) of six studies, a study that addressed nonhypertensive individuals on sustained, high-dose enalapril. Based on a limited base of experiments, ACE inhibitors appear unlikely to adversely affect cognitive functioning and may result in a small advantage for psychomotor speed.
Beta-Blockers
While there are clinical reports of sedation and psychomotor slowing by beta-blockers (e.g., Ades, Gunther, Meacham, Handy, & LeWinter, 1988 ), a systematic review of studies on beta-blockers show inconsistent results. The inconsistency can be explained, in part, by the substantial variability in design methodology and the preponderance of small sample sizes. Alternatively, some have postulated that a portion of this variability can be explained by the lipid solubility of the various beta-blockers that determines their CNS penetration (i.e., high solubility leads to greater penetration; Neil-Dwyer, Bartlett, McAinsh, & Cruickshank, 1981 ). However, a comprehensive review of 32 studies (Muldoon, Manuck, Sha-piro, & Waldstein, 1991) , shows no significant relationship to neuropsychological functioning. The conclusion remains the same for a review of studies since 1991. Muldoon and colleagues observed that the four studies showing improved attention appeared to be associated with greater resistance to distraction, potentially being a function of the anxiety reducing properties of beta-blockers. Interestingly, one of these studies (Bender, Greil, Ruther, & Schnelle, 1979) found positive effects at lower doses of sotalol, but worse performance with high doses compared to placebo. The beneficial effects of anxiety reduction may be mild and appear at low doses while adverse CNS effects may mask such benefits at high doses and actually cause some decrement in performance. These positive attention findings must be weighed against 10 others showing no effect and one showing a negative effect of betablockers (Muldoon et al., 1991) . Overall, any effects of beta-blockers on neuropsychological functioning are likely small in magnitude and may represent a balance of adverse effects with the benefits of improved blood pressure and, for certain patients, clinically beneficial anxiety reduction.
Alpha-Adrenergic Inhibitors and Calcium Channel Blockers
The neuropsychological effects of alpha-adrenergic inhibitors and calcium channel blockers are largely unknown. A search of the experimental literature finds few adequately designed studies addressing these medications and yielding no significant effects (Goldstein et al., 1990; Lasser, Nash, Lasser, Hamill, & Batey, 1989) . While the lack of effects may be attributed to most of these medications having no CNS penetration, there is insufficient research at this point to state with any confidence that there are no clinically significant neuropsychological effects. The state of the literature for these medications is essentially unchanged since Muldoon et al.'s (1991) review.
Conclusions
While there appears to be little data on either short-term administration of antihypertensives or their effect in nonclinical populations, chronic administration to hypertensive individuals has shown mostly little to no adverse or beneficial neuropsychological effects. While still speculative, there is support for the hypothesis that, among the classes of antihypertensive agents, ACE inhibitors as a group may produce a positive influence on psychomotor functioning with potential for a small but significant impact on memory. Beta-blockers may also share the same properties. A large scale meta-analysis (Beto & Bansai, 1992) further supports this speculation. Behavioral management of hypertension may represent a clinically significant advantage over pharmacological interventions in terms of neuropsychological functioning, but this has not been tested directly and should be conducted clinically only in close collaboration with the patient's physician.
ANTIEPILEPTICS
Addressing the neuropsychological effects of antiepileptic drugs (AEDs) is complicated by the wide range of transient and sustained adverse effects of the multiple types of seizure disorders, age, individual differences in the metabolism of AEDs, the drug level(s) at the time of assessment, polypharmacy, interactions with nonantiepileptic drugs, tolerance, concurrent alcohol/sedative use, comorbid hypoxia and head injuries, and prophylactic use following traumatic brain injury. Therefore, any comprehensive review is beyond the scope of this review. What follows is a set of basic guidelines based on the type of drug used and the most prominent individual differences. For a list of cited antiepileptics, see Table 5 .
Phenobarbital
Phenobarbital has long been used for seizure control, especially for partial and generalized tonic-clonic seizures, and enjoys a reputation of generally good relative safety but with significant negative cognitive effects. The most common neuropsychological findings associated with phenobarbital in well-designed studies are sedative-and dose-dependent depressed intelligence test performance (Calandre, Dominguez-Granados, Gomez-Rubio & Molina-Font, 1990; Farwell et al., 1992) , vigilance (for review see Smith, 1991) , memory and psychomotor functioning (MacLeod, Dekaban, & Hunt, 1978) . A general review comparing studies of individuals without neurological or psychological disorders and epileptic patients suggests that nonepileptic individuals experience greater adverse cognitive effects than patients. This is likely a function of the benefits of seizure control in patients (Smith, 1991) . Tolerance to the sedative effects of phenobarbital is most common, but it is unclear how much neuropsychological functioning recovers with tolerance to sedative effects. Withdrawal of phenobarbital, even for seizure-prone patients, appears to result in significant improvement of functioning (Farwell et al., 1992) .
Phenytoin
Less severe impairments result from popular agents, such as phenytoin, carbamazepine, and valproic acid. Yet, these medications are not without their own adverse cognitive effects in many patients. For example, phenytoin has long been known to be capable of producing an acute confusional state even in the absence of nystagmus, ataxia or supra therapeutic doses (Glaser, 1972) . Most well-controlled studies converge on the conclusion that phenytoin produces adverse effects on vigilance, psychomotor functioning, memory, general intelligence testing and school and work performance for many patients and that there are reports of significant dose-dependent effects (e.g., Dodrill, 1975; Thompson, Huppert, & Trimble, 1980 ). An essential caveat in phenytoin research is described by Dodrill (1991) , who warns that some of the adverse cognitive effects may be due entirely to phenytoin-induced deficits in motor speed and accuracy. Furthermore, after Dodrill factored out of reaction time, no significant effects on other cognitive measures were found.
Carbamazepine
Studies of carbamazepine and valproic acid have typically involved comparison with each other, phenytoin, or phenobarbital. Most studies have shown carbamazepine, believed to be less sedating, to have less adverse neuropsychological effects than phenytoin or phenobarbital, but it is not without effect. In a well-controlled study of healthy adults comparing carbamazepine and phenytoin to placebo, some measures showed no effects (Symbol Digit Modalities Test, Selective Reminding Test, Rey-Osterreith Complex Figure, Paced Auditory Serial Addition Test) , and others were significantly impaired relative to placebo (Stroop Interference, Finger Tapping, Grooved Pegboard, and Choice Reaction Time; Meador et al., 1991) . While carbamazepine produced greater impairment than phenytoin for Stroop Interference performance, the opposite was true for Finger Tapping and Grooved Pegboard, consistent with the phenytoin research showing strong motor effects. In another well-controlled study comparing carbamazepine with phenytoin, patients recovering from brain trauma were followed either on drug or on a blinded withdrawal to placebo (Smith et al., 1994) . Small adverse effects on tests emphasizing speeded motor and verbal responses were found for those remaining on drug, again with the phenytoin producing the greatest effect on motor measures and carbamazepine on speeded verbal responses. The large VA cooperative study of 622 previously untreated patients comparing carbamazepine, phenytoin, phenobarbital and primidone (Mattson et al., 1985) , showed all drugs to have significant effects, but that carbamazepine showed the fewest effects, especially on measures of attention/concentration. Thus, while relatively safe among the AEDs carbamazepine still tends to adversely affect some cognitive functions, most notably psychomotor speed.
Valproic Acid
There is a sparse literature on valproic acid. Valproic acid is believed to have less sedative effects than phenobarbital and phenytoin (Smith, 1991) . It appears to have minimal cognitive effects at common clinical doses both in nonepileptic individuals (Trimble & Thompson, 1984) and in patients (Gay, 1984) . However, higher doses and interaction with other AEDs is associated with a greater incidence of adverse effects (Bruni & Albright, 1983; Sommerback et al., 1977) .
Conclusions
In summary, phenobarbital produces the greatest negative neuropsychological effects (psychomotor, memory, attention/concentration and general intelligence) among the AED's. Phenytoin has a generally smaller effect but significant sedative-and dose-dependent motor speed and accuracy and memory effects persist. Withdrawal of phenobarbital and, to a lesser extent, phenytoin generally produce significant improvement. The effects of frequently significant psychomotor slowing on a range of test performances must be considered. Carbamazepine and, probably, valproic acid have the smallest adverse effects, likely relating to low sedative properties. However, both drugs do show important effects at higher doses and during polypharmacy. Tolerance is partial among the AEDs, but there is wide variability. Finally, a wide range of variables must go into the assessment of neuropsychological functioning for patients on AEDs, most importantly, dose, chronicity of treatment, and sedation.
ANTIHISTAMINES
Although antihistamines are typically used for sinusitis and other allergic reactions, many have the potential for adverse neuropsychological effects. Thus, these common prescription and non-prescription medications require attention in the assessment process. These agents are taken by approximately 30 million Americans each year (Meltzer, 1990) . By far, the most important factor in determining the cognitive effects of these H 1 antagonists is the subclass to which they belong. Traditional or first-generation antihistamines (e.g., diphenhydramine, chlorpheniramine, clemastine) are all sedating due to their lipid-solubility and their crossing of the blood-brain barrier that enable direct CNS effects (Burkhalter, Julius, & Frick, 1995) . By contrast, second-generation antihistamines (e.g., terfenadine, astemizole, loratadine) are peripherally acting and cause little or no sedation. In practice, many of these drugs, especially the first-generation antihistamines, are combined with decongestants, such as pseudoephedrine, which have stimulant properties. Adequately designed clinical trials of sedating antihistamines produce dose-dependent deficits in psychomotor functioning, attention/concentration, memory, and practical skills, such as driving. Interestingly, it may be the central antimuscarinic properties of these antihistamines that may be primarily responsible for the sedative effects (Murkhalter, Julius, & Frick, 1995) . Furthermore, it may be this anticholinergic effect that may lead to memory impairment at moderate to high doses. The second-generation antihistamines routinely show superiority over the sedating agents on all measures typically impaired by the latter and rarely show deficits relative to placebo (e.g., Hindmarch & Bhatti, 1987; Nicholson & Stone, 1982; Patat et al., 1994; Tharion, McMenemy, & Rauch, 1994) . For a list of cited antihistamines, see Table 6 .
Conclusions
In conclusion, older sedating antihistamines yield significant psychomotor, attentional and, to a lesser extent, memory performance decrements that are associated with impairment in daily activities such as driving and operation of dangerous equipment. Such sedation and associated psychomotor impairment may be especially dangerous to the elderly. The nonlipophilic/nonsedating antihistamines are clearly superior and appear no different from placebo. Since clinical trials have focused on single-dose administration to mimic the ''as needed'' dosing commonly used by patients, the issues of chronic effects and tolerance have not been adequately addressed in the literature. Finally, it should be remembered that those with rhinitis for whom these medications are most commonly used, may be suffering from fatigue or sedation independent of any medication.
SUMMARY AND CONCLUSIONS
Among the anxiolytics, benzodiazepines all produce sedative, psychomotor, concentration, and memory decrements while the atypical anxiolytic, buspirone, is substantially more benign, though a significantly longer time for desired therapeutic benefit. TCAs are of most concern within the antidepressant class with acute psychomotor and concentration effects ϩMild adverse cognitive effects; ϩϩ moderate adverse cognitive effects; ϩϩϩ large adverse cognitive effects; 0 no adverse cognitive effects. *Data suggest nonlinear effects with potential improvement at low doses and impairment at high doses. **Data presented assuming monotherapy; polypharmacy can cause much more variable effects. #Insufficient human studies, but minimal CNS activity suggest little to no effect is probable. ##Insufficient human studies.
and persisting anti-cholinergic-associated memory impairment. SSRIs are relatively safer, but not without adverse effects. Both SSRIs and MAOIs are in need of more definitive study. Antihypertensives generally produce moderate to no significant cognitive effects, but this is an area clearly in need of further study with particular attention to the effects of cerebrovascular compromise and potentially positive effects of blood pressure control. ACE inhibitors and beta-blockers may produce a positive influence on psychomotor functioning with potential for a small but significant impact on memory. Seizure patients administered antiepileptics appear to benefit from seizure control, but phenobarbital typically overcomes any potential benefit with heavy sedation and negative effects on a wide range of functioning. Carbamazepine, valproic acid and, to a lesser extent, phenytoin, produce more mild effects. Phenytoin specifically effects motor speed and accuracy while carbamazepine's effects may be more in slowing verbal responses. Newer AEDs have not been adequately addressed in the literature despite claims regarding their relative cognitive safety. Finally, sedative antihistamines negatively impact psychomotor function, vigilance, adaptive measures, such as driving and memory, while nonsedating antihistamines are essentially devoid of any adverse cognitive effects. A summary of the findings for attention, psychomotor speed and memory effects of these drugs is found in Table 7 . The current review of antidepressants, anxiolytics, antihypertensives, antiepileptics, and antihistamines converge on the central issues of sedative and anticholinergic properties in the production of neuropsychological impairments. Importantly, sedative effects of these drugs commonly diminish with chronic administration and show a concomitant reduction in psychomotor and, to a lesser extent, attentional effects. By contrast, drug-induced memory deficits appear most closely associated with anti-cholinergic effects, which show little or no tolerance. Such memory effects tend to persist beyond the time that many patients cease reporting memory complaints. Language, visuospatial skills and, to a lesser extent, executive functioning appear relatively resistant to most drug effects, especially when there are minimal psychomotor and speeded components in measures of these cognitive domains.
While the neuropsychologist would be expected to be well-versed in the psychological and neurological conditions for which these drugs are commonly administered, the integration of this knowledge with what is known about the influence of these pharmacotherapeutic agents has commonly been lacking. Primary factors that should be integrated more fully into the typical neuropsychological assessment of patients taking these medications are: (a) chronicity of drug administration, especially for highly sedating drugs, such as benzodiazepines and barbiturates, (b) metabolic capacity, with focus on the elderly, those on multiple medications, and those with compromised liver or renal functioning, (c) the positive neuropsychological effects of disease management whether by pharmacological or psychotherapeutic means, (d) a direct comparison of speeded versus nonspeeded tasks within cognitive domains, and (e) the temporal onset of patient/significant other cognitive complaints with respect to drug initiation/cessation and increase/reduction.
The literature includes a large proportion of preliminary studies with less sophisticated designs or with low-powered sample sizes. A minority of studies address more than one cognitive domain, most commonly psychomotor functioning. A majority of cognitive tests used in this research are commonly lacking in validation studies, reliability or normative data. Furthermore, these studies are typically conducted in the context of clinical drug trials by researchers primarily trained in psychopharmacology rather than in neuropsychology. It should be remembered that there is a substantial base of data that is never submitted to publication at the discretion of the drug manufacturers that supported the studies. This may be an especially acute problem for newer agents and those that have little or no competition in their class among FDA-approved drugs.
